Plenary Congress Day 1

MORNING PLENARIES RENAISSANCE BALLROOM

Gregory Poland
08:20

Chair’s opening remarks

Dr Gregory A. Poland, Director of Mayo Vaccine Research Group, Mayo Clinic
Panel discussion
08:30

Opening plenary keynote insights: What direction will vaccines take to ensure safety and mass immunization? Vaccine research and development in the public sector

  • What kind of regulatory and political support can we expect?
  • Prevention and pre-prepared efforts to ensure our current and future safety
  • Vaccine development and innovation including the current landscape, existing challenges, and drivers and levers to incentivize development
Panel discussion
10:20

Networking Coffee Break

INTERACTIVE ROUNDTABLES

11:20

Artificial intelligence -adopting cognitive computing across the PV landscape

11:20

Best practices for a Successful CRO/Pharma partnership for vaccine clinical studies

Marc Hoffman
11:20

Challenges for development of GMO vaccines

Marc Hoffman, Chief Medical Officer & Aernout van Haarst, Director Scientific Affairs, Celerion
11:20

Changing landscape of real-world evidence and its impact on clinical research – uncovering lab & clinical adverse events

Dr James Cummings
11:20

Developing more effective vaccines for emerging/re-emerging pandemic threats

Dr James F. Cummings, MD, President, ICON Government and Public Health Solutions – title TBC
11:20

Development of novel predictive algorithms for patient selection

11:20

Oncology – applying informatics to find the best treatment option for each patient

11:20

Overcoming obstacles to improve cold chain management of biologics

Dr Nathalie Garcon
11:20

Safety evaluation of vaccines: from now to tomorrow, new approaches and technologies?

Dr Nathalie Garcon, CSO & CEO, Bioaster
Cynthia Dukes
11:20

Seasonal vaccine studies: Critical success factors

Cynthia Dukes, VP, Scientific and Clinical Services and Head of Vaccine Center of Excellence, ICON Clinical Research – title TBC
11:20

The use of ePRO solutions and platforms in vaccine studies

Senior representative, PPD
Dr Jun Tang
11:20

When limited patient resources meet unlimited immunotherapy combinations—the strategies to develop clinical IO agents in platform studies

12:40

Networking Lunch (Exhibition Hall)

AFTERNOON PLENARIES

Rino Rappuoli
14:10

The role of vaccines to combat antibiotic-microbial resistance

  • What can we do to manage AMR? The mis-use of Abx in bacterial and viral infections
  • How vaccine regulatory and access policies can be used to strengthen utilization of vaccines as a component of multi-pronged strategies that governments should take in their national action plans to address AMR
  • The need for a holistic and collaborative strategy including cross species considerations
Panel discussion
15:00

Fire chat: The future of the vaccine business from the executives

  • What vaccines will they invest in and why
  • How will we translate data heavy tools into translational precision medicines?
  • Can we continue to be dependent on industry for process development and advanced clinical development, especially for products destined for LMICs?
  • Should it be industry’s responsibility to help address vaccine hesitancy?
Johan Van Hoof, Global Therapeutic Area Head Of Infectious Diseases And Vaccines And Managing Director, Johnson & Johnson
16:00

Networking Coffee Break

AFTERNOON PLENARIES

ONE HEALTH

Plenary afternoon day 1
16:40

The continuing instrumental role of NGOs: Making the impossible, achievable

  • What global market trends can we expect in the next 10 years? What does this mean for vaccines?
  • Impact of emerging diseases, AMR and measles outbreaks
  • Ongoing efforts towards developing world diseases and child health
  • Strengthening of primary health care systems
ONE HEALTH
16:40

One Health pharma strategy update

  • Examining the strategic context, rationale and case for investing in One Health
  • How are the veterinary pharma companies working towards a implementing a One Health approach?
Plenary afternoon day 1
17:40

The resurgence of immuno-oncology – Can they hold their promise?

  • How will recent breakthroughs in immuno-oncology shape the way we design cancer vaccines and combinational treatments?
  • Are our expectations vs the reality of immunotherapies working aligned?
  • How can we better characterize post-treatment analysis of anti-tumor immune responses to develop more effective immunotherapy approaches?
  • Advancements in personalized neoantigen vaccines and novel targets
ONE HEALTH
17:40

Operational framework for strengthening human & animal public health systems at their interface

  • What tools and resources from the human health, animal health, and disaster risk reduction sectors can facilitate multi-sectoral coordination?
  • Strategy for appropriate One Health entry points and a pathway to the prevent-detect-respond-recover spectrum of preparedness
  • What public health system changes do we need to truly facilitate a One Health approach?
18:40

Chair’s Closing Remarks and Close of Congress Day 1

18:50

Pre-Awards Networking Drinks Reception (off-site)

19:30

Gala Dinner & 12th Annual ViE Awards Ceremony

last published: 18/Jan/19 09:26 GMT

Sign Up for Event Updates

Get Involved At World Vaccine Congress Washington

 

To Sponsor Or Exhibit

Marc Rhys-Evans
marc.rhys-evans@terrapinn.com
+44 20 7827 5945

 

 

 

To Register

Tayyab Abbasi
tayyab.abbasi@terrapinn.com
+44 20 7092 1210

 

 

 

Press Relations

Karina Kusova
karina.kusova@terrapinn.com
+44 20 7092 1071